Relmada Therapeutics (RLMD) Misses Q4 EPS by 1c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.84), $0.01 worse than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral